NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

Yup…Still up there!

DCVax® – L Phase III for GBM Brain Cancer
Status: Enrollment Completed in 2015
For a complete listing of clinical trial sites, details, and contact information please Click Here.

Our lead product is DCVax-L for Glioblastoma multiforme (“GBM”), the most lethal form of primary brain cancer. We have completed two Phase I/II trials and are now well under way with a large Phase III trial, as described below.

With full standard of care treatment for GBM today, including surgery, radiation and chemotherapy, the median time from surgery to remove the initial tumor to the time of tumor recurrence is just 6.9 months, and median survival is just 14.6 months. There has been very little improvement in clinical outcomes for GBM patients in the last 30 years. The incidence of GBM appears to be on the rise, for unknown reasons, and there is an urgent need for new and better treatments.